Vaxxas, a clinical-stage biotechnology company commercializing a novel high-density microarray patch (HD-MAP) vaccination platform, has been named a C ...

Protein microarrays are prepared by spotting 1 of a ligand pair, such as an antigen or an antibody, on microslides or microchips in very little volume.

Trial represents first-ever CDC-sponsored clinical trial of vaccine delivered via “patch” technology and utilizes Micron’s first-in-class dissolvable microarray technology Research builds on ...

Atlanta (June 16 2025)-- Emory University and Micron Biomedical today announced the first clinical trial of a novel rotavirus vaccine, CC24, delivered via dissolvable microarray technology, is now ...